Loading... Please wait...

Latest Reports

 


Published:
August 2016

See Report Details
Medical Imaging Markets

TriMark Publications This TriMark Publications report describes nine main medical imaging sectors: X-ray, ultrasound, computed tomography (CT), positron emission tomography (PET), single photon emission tomography (SPECT), magnetic resonance imaging (MRI), nuclear medicine (NM), mammography and fluoroscopy. This report covers:

  • Globally, X-ray is the most frequently used imaging procedure with about 108 million X-ray exams per year. MRI is second with 26 million examinations per year. PET, SPECT, CT and nuclear medicine rank third with 30 million examinations per year.
  • Picture archiving and communication systems (PACS) and contrast agents are the sub-segments in medical imaging market that have gained significant growth in recent years.
  • The global medical imaging industry is primed to experience significant growth through the next decade.
  • This report surveys almost all of the companies known to be marketing, manufacturing or developing medical imaging equipment and supplies in the world.
  • An overview of the global market for medical imaging.
    Analyses of global market size, with data from 2015, with estimates for 2016, and projections through 2021.
  • Estimates of growth, trends, key issues and drivers in medical imaging through 2021.
  • A discussion of business activity in this sector with possible new company entrants to the market.
  • Discussion of related issues, such as growth regulators, government regulation, reimbursement trends and revenue threats, as well as sector consolidation, acquisition & licensing.
  • Innovative technology platforms and data management and connectivity.
  • Comprehensive company profiles of major players in the field.

 

Sample Figure from Report
 
See Report Details




Published:
August 2016

See Report Details
Point of Care Diagnostic Testing World Markets

TriMark Publications estimates that the global market for point of care testing was $12.9 billion in 2015. This segment is expected to reach $16.7 billion in 2018, with a compound annual growth (CAGR) of 8.6% over the next five years. This report provides:

  • An overview of the global market for point of care testing.
  • Analyses of global market size, with data from 2008 to 2015, estimates for 2016, and projections through 2018.
  • The U.S. and important international markets are analyzed. The U.S. is recognized as the largest single country market for POCT products; Europe represents the largest regional market for POCT products. Asia (which includes Japan, China and India for the purposes of this report) represents a major market, but there are significant differences in growth rates for each of the individual countries.
  • Estimates of growth, trends, key issues and drivers in point of care IVD testing through 2018.
  • An overview of point of care testing, with particular emphasis on market size and growth rate for glucose monitoring, blood gas & electrolytes, coagulation, cardiac markers, substance abuse, infectious disease, urine strip tests, pregnancy tests, occult blood and cholesterol for each major country market.
  • A discussion of business activity in this sector with possible new company entrants to the market.
  • A discussion of related issues, such as growth regulators, government regulation, reimbursement trends and revenue threats, as well as sector consolidation, acquisition & licensing.
  • Innovative technology platforms and data management and connectivity.
  • Comprehensive company profiles of major players in the field of point of care testing.

 

Sample Figure from Report
 
See Report Details




Published:
August 2016

See Report Details
Cardiac Marker Diagnostic Testing Markets

TriMark Publications estimates that the global market for in vitro diagnostic tests for cardiac biomarkers will be worth $7.2 billion in 2016. This segment is expected to reach $13.1 billion in 2021, growing at a compound annual growth (CAGR) of 11.5% over the next five years. This report provides:

  • An overview of the global market for in vitro diagnostic (IVD) tests for cardiac biomarkers.
  • Analyses of global market size, with data from 2011 to 2015, estimates for 2016, and projections through 2021.
  • The U.S. and important international markets are analyzed. The U.S. is recognized as the largest single country market for cardiac biomarker IVD and point of care (POC) products.
  • Estimates of growth, trends, key issues and drivers in cardiac biomarker testing through 2021.
  • An overview of point of care testing with particular emphasis on market size and growth rate for individual cardiac markers for major markets.
  • An overview of testing for biomarkers of cardiovascular disease, including sudden cardiac arrest (SCA), acute myocardial infarction (AMI), congestive heart failure (CHF) and atherosclerosis.
  • A discussion of business activity in this sector, including strategies for growth in emerging markets.
  • A discussion of related issues, such as growth regulators, government regulation, reimbursement trends, as well as sector consolidation, acquisition & licensing.
  • Comprehensive company profiles of major players in the field of cardiac biomarker testing.

 

Sample Figure from Report
 
See Report Details
 


Published:
June 2016

See Report Details
Molecular Diagnostics in Cancer Testing

TriMark Publications estimates that the global market for molecular diagnostics for cancer testing is $1.77 billion in 2016. This segment is expected to reach $3.52 billion in 2021, with a compound annual growth (CAGR) of 24% over the next five years. This report provides:

  • An overview of the global market for molecular diagnostics in cancer testing.
  • Analyses of global markets size, including data from 2012 to 2015 with estimates for 2016 and projections through 2021. The U.S. and international markets are analyzed.
  • Estimates of growth and trends in cancer testing through 2021.
  • An overview of cancer testing, with particular emphasis on breast, ovarian, prostate, lung, colorectal and melanoma cancers.
  • A discussion of business activity in this sector with possible new company entrants to the market.
  • A discussion of related issues, such as government regulation, reimbursement trends and revenue threats.
  • Comprehensive company profiles of major players in the field of molecular diagnostics in cancer testing.

 

Sample Figure from Report

See Report Details




Published:
May 2016

See Report Details
Molecular Diagnostics in Infectious Disease Testing

TriMark Publications estimates that the global market for molecular diagnostics for infectious disease testing is $4.1 billion in 2016. This segment is expected to reach $5.9 billion in 2020, with a compound annual growth (CAGR) of 21% over the next five years. This report provides:

  • An overview of the global market for molecular diagnostics for infectious disease testing. Analyses of global market size, with data from 2012, 2013,2014, and 2015, with estimates for 2016, and projections through 2020. The U.S. and international markets are analyzed.
  • Estimates of growth and trends in advanced MD infectious disease testing through 2020.
  • An overview of infectious disease testing, with particular emphasis on hepatitis, HIV, human papilloma virus, influenza, STD Testing (including Chlamydia/Gonorrhea Molecular Diagnostic Testing), tuberculosis, Methicillin-Resistant Staphylococcus aureus (MRSA) and Vancomycin-Resistant Enterococci.
  • A discussion of business activity in this sector with possible new company entrants to the market.
  • A discussion of related issues, such as government regulation, reimbursement trends and revenue threats.
  • Comprehensive company profiles of major players in the field of molecular diagnostics for infectious disease testing.

 

Sample Figure from Report
 
See Report Details




Published:
March 2016

See Report Details
Global Flow Cytometry Markets

TriMark Publications estimates the high growth global flow cytometry market to generate $5.9 billion revenue by 2020. The global flow cytometry market--one of the fastest growing segments of the life sciences and clinical diagnostics markets--is projected to grow from $3.3 billion on 2015 to $5.9 billion in 2020 at an annualized rate of 12%. This dynamic market is driven by rapidly growing flow cytometry applications in development of new cancer immunotherapies, vaccines for infectious diseases that threaten global health, stem cell and regenerative medicine, and biomarkers for personalized medicine.

This report provides the latest up-to-date flow cytometry market analysis with revenue data from 2014 and 2015, estimated 2016 market revenue, and forecasts through 2020. The U.S. is the largest flow cytometry market worldwide, followed by Western Europe. Rapid growth of 17% from 2015 to 2020 is projected for the emerging countries of China, India and Brazil.

Clinical research testing in these countries by CROs using flow cytometry is a leading growth factor. Diagnostic tests for influenza and tropical diseases using multiplex flow cytometry is a growing opportunity in these regions. Brazil is partnering with manufacturers of flow cytometry multiplex systems and developing diagnostic tests for the Zika and other mosquito borne viruses for use in Latin America. ‘

There is a major market opportunity for flow cytometry instruments, reagents, and POC analyzers in resource limited countries affected by the HIV/AIDS epidemic. In 2015, the WHO issued new guidelines for ART treatment of those at risk, almost doubling the number of people who can be treated and thus monitored by flow cytometry CD4 testing for progression of the disease.

The new technologies of flow cytometry imaging and mass cytometry are enabling more applications. In this report is an analysis of next generation technologies including microfluidics cell sorters, microchip imaging, and integration of flow cytometry with smartphone technology.

 

Sample Figure from Report
 
See Report Details